retatrutide nonalcoholic steatohepatitis trial fatty liver disease Current therapies and new developments in NASH retatrutide nonalcoholic fatty liver disease – retatrutide nonalcoholic fatty liver disease

Most patients experience constipation most noticeably during dose escalationwhen your dose may need to go up over the first month of treatment

W.GarfieldA

We're here when you need us

What Kind of Compensation May Be Available

As Turner explains, Meeting your protein needs on GLP-1 medications is very important because reduced appetite and quicker fullness can lead to eating less overall, increasing the risk of losing muscle instead of fat. She recommends spreading protein across the day in smaller, more tolerable servings. This can help with more consistent protein intake at both meals and snacks, rather than trying to force down one large shake or a big protein-heavy dinner when youre already full

This usually subsides as the body adjusts, and adequate hydration paradoxically helps reduce retention